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Abstract
In clinic, cetuximab, an anti-EGFR antibody, improves treatment outcomes in colorectal
cancer (CRC). KRAS-mutant CRC is generally resistant to cetuximab, although difference
of the sensitivity among KRAS-mutants has not been studied in detail. We previously devel-
oped the cancer tissue-originated spheroid (CTOS) method, a primary culture method for
cancer cells. We applied CTOS method to investigate whether ex vivo cetuximab sensitivity
assays reflect the difference in sensitivity in the xenografts. Firstly, in vivo cetuximab treat-
ment was performed with xenografts derived from 10 CTOS lines (3 KRAS-wildtype and 7
KRAS mutants). All two CTOS lines which exhibited tumor regression were KRAS-wildtype,
meanwhile all KRAS-mutant CTOS lines grew more than the initial size: were resistant to
cetuximab according to the clinical evaluation criteria, although the sensitivity was quite
diverse. We divided KRAS-mutants into two groups; partially responsive group in which
cetuximab had a substantial growth inhibitory effect, and resistant group which exhibited no
effect. The ex vivo signaling assay with EGF stimulation revealed that the partially respon-
sive group, but not the resistant group, exhibited suppressed ERK phosphorylation ex vivo.
Furthermore, two lines from the partially responsive group, but none of the lines in the resis-
tant group, exhibited a combinatory effect of cetuximab and trametinib, a MEK inhibitor, ex
vivo and in vivo. Taken together, the results indicate that ex vivo signaling assay reflects the
difference in sensitivity in vivo and stratifies KRAS mutant CTOS lines by sensitivity. There-
fore, coupling the in vivo and ex vivo assays with CTOS can be a useful platform for under-
standing the mechanism of diversity in drug sensitivity.







Citation: Tashiro T, Okuyama H, Endo H, Kawada
K, Ashida Y, Ohue M, et al. (2017) In vivo and ex
vivo cetuximab sensitivity assay using three-
dimensional primary culture system to stratify
KRAS mutant colorectal cancer. PLoS ONE 12(3):
e0174151. https://doi.org/10.1371/journal.
pone.0174151
Editor: Ajay Goel, Baylor University Medical Center,
UNITED STATES
Received: November 2, 2016
Accepted: March 3, 2017
Published: March 16, 2017
Copyright: © 2017 Tashiro et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This work was supported in part by
grants-in-aid from P-DIRECT
(15cm0106155h0002), and P-CREATE
(16cm0106203h0001), Japan Agency for Medical
Research and Development (MI, HO, and HE) and
the Takeda Science Foundation (MI). Charles River
Laboratory Japans provided support in the form of
Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer prevalence and death world-
wide. Treatment of CRC has progressed by the recent development of new drugs, such as oxa-
liplatin and irinotecan, as well as molecular target drugs, such as cetuximab, panitumumab,
bevacizumab, aflibercept, regorafenib, and ramucirumab [1–3]. Anti-EGFR antibodies, cetuxi-
mab and panitumumab, have contributed remarkably to the treatment of metastatic CRC,
though CRCs with KRASmutations at codons 12 and 13 are resistant to these antibodies [4–
6]. NRASmutations and mutations at other codons in KRAS also reportedly contribute to
cetuximab resistance [7–9]. Currently, expanded RAS wildtype CRCs (KRAS and NRASwild-
type) are candidates for anti-EGFR therapy [1]. To improve treatment outcomes for CRC, it is
important to develop effective therapies for RAS mutants.
Established cancer cell lines have contributed to the study of cancer and development of
new drugs, though discrepancies are often observed between experimental results and clinical
trials, possibly due to changes or severe selection during the establishment and passage of cells
in vitro [10, 11]. Inter-patient heterogeneity may not be maintained in established cell lines
[12, 13]. On the other hand, patient-derived xenografts (PDXs) better preserve the original
characteristics of patient tumors, and the assay results reflect the clinical trials [12–17]. How-
ever, the costly and time consuming assay of PDXs is not suitable for testing multiple candi-
date drugs or studying detailed signaling pathways.
Previously, we developed the cancer tissue-originated spheroid (CTOS) method, a prepara-
tion and culture method for primary cancer cells from patient tumors[18]. By maintaining
cell-cell contact throughout the process, we can avoid anoikis and prepare pure cancer cells
stably and efficiently. We previously reported the successful preparation of CTOSs from vari-
ous cancers, including colon, lung, bladder, brain, and uterine cancer [18–23]. CTOSs preserve
the original characteristics both ex vivo and in vivo [18–20, 22, 23]. CTOSs can also be pre-
pared efficiently from CTOS-derived xenograft tumors and subjected to ex vivo experiments.
As CRC PDX models have been reported to reflect the results of clinical trials for cetuximab
[14–17], we investigated whether an ex vivo cetuximab sensitivity assay using CTOSs can
reflect the results of an in vivo study using CTOS xenografts. Using the ex vivo platform, we
attempted to find biomarkers and the effective drugs to combine with cetuximab for KRAS
mutant CRC.
Materials and methods
CTOS preparation, culture, and cryopreservation
The preparation of CTOSs from CRC patients was performed as described previously [18].
Briefly, surgical specimens were obtained from Osaka Medical Center for Cancer and Cardio-
vascular Diseases after obtaining informed consent. The surgical specimens were mechanically
and enzymatically digested into small fragments. Materials retained by 100 μm or 40 μm cell
strainers (BD Falcon, Franklin Lakes, NJ) were collected and cultured in suspension in Stem-
Pro hESC (Invitrogen, Carlsbad, CA) with 8 ng/ml of bFGF (Invitrogen) to form CTOSs. Fro-
zen stocked CTOSs were thawed and xenograft tumors generated as described above. CTOSs
were prepared from the xenografts and subjected to further analysis. Cryopreservation was
performed using StemCell Keep (BioVerde, Kyoto, Japan).
Animal studies
Animal studies were approved by the Institutional Animal Care and Use Committee of Osaka
Medical Center for Cancer and Cardiovascular Diseases and performed in compliance with
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the institutional guidelines. For cetuximab mono-therapy, a mixture of CTOSs and Matrigel
was transplanted into the flank of NOD/SCID mice (Charles River Laboratories Japan, Yoko-
hama, Japan). When the tumor reached 160 mm3, cetuximab was injected intraperitoneally
twice a week at 20 and 60 mg/kg. For the combination therapy, tumors were generated as
described above using BALB/cAJcl-nu/nu mice (CLEA Japan, Tokyo, Japan). When the tumor
reached 300 mm3, cetuximab was injected intraperitoneally twice a week at 20 mg/kg and tra-
metinib administrated orally every day at 0.3 mg/kg. Trametinib was suspended in 0.5%
methyl cellulose with 0.2% Tween80. Tumor size was measured twice a week and the tumor
volume calculated as follows: 0.5 x width2 x length. For ethical reasons mice bearing an exces-
sive tumor volume (>2,000 mm3) were euthanized.
Grouping of CTOS lines by sensitivity to cetuximab in vivo
CTOS lines were classified into three groups according to their sensitivity to cetuximab. The
regression group consisted of the lines in which the average tumor volume at day 11 was the
same or less than the average starting volume. The partially responsive group consisted of lines
in which the average tumor volume was suppressed more than 10% compared to the average
volume of non-treated tumors but did not show regression. The resistant group consisted of
lines in which the average tumor volume at day 11 was suppressed less than 10% compared to
the average volume of non-treated tumors.
Mutational analysis
Mutational analysis was performed using Ion AmpliSeq™ Cancer Hotspot Panel v2 (Thermo-
Fisher, Waltham, MA) and next-generation sequencing (TAKARA, Kusatsu, Japan).
Immunohistochemistry
Formalin-fixed paraffin-embedded samples were used for immunohistochemistry as described
previously [18]. Antigen retrieval was performed by autoclave incubation in citrate buffer (pH
6.0). Primary antibody specific for the EGFR (clone D38B1) was obtained from Cell Signaling
Technologies (Danvers, MA). Images were acquired using the CellSens standard imaging soft-
ware (Olympus, Tokyo, Japan). Hematoxylin was used for counter staining. The staining
intensity was evaluated as low if membranous staining was present in less than 10% of tumor
cells, med if membranous staining was present in 10% to 50% of tumor cells, and high if mem-
branous staining was present in more than 50% of tumor cells.
Reagents
Trametinib was purchased from Selleck Chemicals (Houston, TX, USA). Drug screening was
performed using SCADS Inhibitor Kit IV. The drugs were dissolved in DMSO and used below
0.1% DMSO.
CTOS-based sensitivity assay
After CTOS preparation, the CTOSs were cultured in suspension overnight in the standard
CTOS medium (StemPro hESC plus bFGF). Each CTOS was embedded in a gel droplet of
Matrigel GFR (BD Biosciences, Bedford, MA) and cultured for 7 days in the standard CTOS
medium or DMEM containing 10% fetal bovine serum (FBS medium) containing the indi-
cated doses of cetuximab. In the case of neuregulin 1 (NRG1) / heregulin (HRG) stimulation,
10 ng/ml of HRG (Peprotech, Rocky Hill, NJ) was added to the FBS medium. The effect was
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evaluated by comparing the area of the spheroid to that of day 0 as measured using Image J
software. (National Institutes of Health, Bethesda, MD).
Reconstituted spheroid-based sensitivity assay
After washing the CTOSs with PBS, they were dissociated into single cells using 0.25% trypsin/
EDTA and filtered through a 40 μm cell strainer (BD Falcon). Approximately 1x104 cells/100ul
were seeded in poly-HEMA-coated 96-well plates and cultured in the FBS medium and 10 μM
of ROCK inhibitor Y27632 (Wako, Osaka, Japan). Each drug was added and the CTOSs cul-
tured for 7 days. ATP content was measured at day 7 by CellTiter-Glo Luminescent Cell Via-
bility Assays (Promega, Madison, WI, USA) and adjusted to the content of the vehicle-treated
control.
Western blot
For signaling assays using CTOSs, the medium was changed to the basal medium (DMEM/
F12 containing 1.8% BSA, 1x nonessential amino acids, 100 U/ml penicillin, 100 μg/ml strep-
tomycin [all from Invitrogen], 0.1 mM β-mercaptoethanol [Wako]), the standard CTOS
medium, or the FBS medium the day after CTOS preparation. The CTOSs were cultured over-
night, treated with 100 nM cetuximab for 2 hours, and the samples collected. For signaling
assays using reconstituted spheroids, the spheroids were treated with the drugs 2 days after re-
aggregation and samples collected 2 hours after treatment. In the case of EGF stimulation, 10
ng/ml of EGF (Invitrogen) was added 15 min before sample collection. Immunoblots were
performed as described previously [18]. Primary antibodies against EGFR (clone D38B1),
pEGFR (Tyr1068) (clone D7A5), pHER2 (Y1221/1222) (clone 6B12), pHER3 (Tyr1289) (clone
21D3), AKT (clone 40D4), pAKT (Ser473) (clone D9E), p44/42 MAPK (clone 3A7), and pp44/
42 MAPK (Thr202/Tyr204) (clone D13.14.4E) were obtained from Cell Signaling Technolo-
gies, and anti β-actin (clone AC-15) from Sigma-Aldrich (St. Louis, MO).
Statistical analysis
One-way or two-way ANOVA followed by Bonferroni’s post-test was used for comparisons of
multiple groups, and correlations were analyzed by Pearson’s correlation using GraphPad
Prism 6 software (San Diego, CA). P<0.05 was considered significant.
Results
In vivo cetuximab sensitivity assay using CTOS lines stratified KRAS
mutant colorectal cancer
We established 10 CTOS lines from patients with CRC (Table 1). Among these 10 lines, three
were KRAS-wildtype and seven were KRASmutants. CTOSs were injected subcutaneously
into NOD-SCID mice to create CTOS-derived xenografts, which were subjected to the cetuxi-
mab sensitivity assay in vivo. The sensitivity varied among the lines, some of which exhibited
tumor regression (regression group), a partial response (partially responsive group), or resis-
tance (resistant group) (Fig 1A). EGFR staining did not correlate with cetuximab sensitivity in
the xenograft tumors (Fig 1B) as previously reported for clinical samples [24]. The clinically
used waterfall plot, in which tumor volume is compared to the volume at the starting point, is
shown in Fig 1C. Both lines in the regression group were KRAS-wildtype, whereas all of the
KRASmutants grew more than the initial volume and were in the partially responsive or resis-
tant groups. The results were compatible with previous clinical reports and studies using PDX
mouse models [5, 15–17].
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Experimental settings allowed growth reduction to be assessed from control (vehicle
treated) tumors (Fig 1D). The difference between the partially responsive group and resistant
group was clear. Thus, KRASmutant CTOS lines were divided into two groups by cetuximab
sensitivity: the partially responsive group and the resistant group. We assessed hotspot muta-
tions of 50 genes. Neither KRASmutation type nor any single mutation correlated with the dif-
ference (Table 1).
Optimizing conditions for ex vivo cetuximab sensitivity assay for CTOSs
To investigate whether in vivo and ex vivo cetuximab sensitivity assays correlate, we tested the
C132 CTOS line from the in vivo regression group. CTOS growth was not suppressed by
cetuximab in the standard CTOS medium (Fig 2A). The media contained HRG [19], a ligand
of HER3, the activation of which has been reported to be one of the mechanisms of cetuximab
resistance [15, 25]. Alternatively, we examined another media containing 10% fetal bovine
serum (FBS medium), and found that C132 CTOSs were sensitive to cetuximab (Fig 2A). The
basal status of intracellular signaling revealed a remarkable difference between the media. In
the standard CTOS medium, basal levels of HER3 and AKT phosphorylation were higher (Fig
2B), and AKT and ERK phosphorylation was suppressed less by cetuximab than in the FBS
medium (Fig 2C). Adding HRG to the FBS medium abolished the growth inhibitory effect of
cetuximab (Fig 2D). Thus, HER3 activation by HRG in the standard CTOS medium obscured
the effect of cetuximab ex vivo. In addition, to reduce the deviation in growth among CTOSs
(Fig 2A), we dissociated C132 CTOSs into single cells and reconstituted the spheroids by cul-
turing the cells at high density in a low attachment culture dish. The decrease in deviation was
prominent in the assay using reconstituted spheroids compared to CTOSs (Fig 2A and 2E),
and the relative ATP levels were confirmed to be remarkably decreased by cetuximab treat-
ment in the FBS medium but not the standard CTOS medium (Fig 2E). Using the reconsti-
tuted spheroids, phosphorylation of EGFR, AKT, and ERK was suppressed by cetuximab
treatment with or without EGF stimulation (Fig 2F). Therefore, we applied the reconstituted
spheroids in FBS medium in further evaluations.
Table 1. Clinical and genomic profiles of 10 CTOS lines.
Clinical Information Mutational status of CTOS
Sample ID Patient sex Tumor location Tumor histology TNM stage KRAS NRAS BRAF PIK3CA AKT1 APC TP53
C166 F Ra Mod ⅢB WT WT WT WT WT WT WT
C132 F T Mod ⅢB WT WT WT WT WT MT WT
C111 F Rs Mod ⅣB WT WT WT WT WT MT MT
C138 F A Mod ⅡA G12A WT WT WT WT MT WT
C45 M Ra Mod ⅣA G12D WT WT WT WT MT WT
CB3 F A Well ⅡA G12V WT WT WT WT MT WT
C97 F Rb Mod ⅢC G13D WT WT MT WT WT MT
C86 M S Mod ⅣA G12V WT WT WT WT MT MT
C75 F Ra Mod ⅣA G13D WT WT WT MT MT WT
C48 M Rab Mod ⅡA K117N WT WT MT WT MT WT
Patient sex: M, male; F, female. Tumor location: A, ascending colon; T, transverse colon; S, sigmoid colon; Rs, rectosigmoid; Ra, upper rectum; Rb, lower
rectum. Tumor histology: Well, well differentiated adenocarcinoma, Mod, moderately differentiated adenocarcinoma. Mutational status of CTOS: A panel of
50 frequently mutated genes in cancer was annalyzed. No mutations other than those mentioned above were detected. WT, wild type, MT, mutant.
Mutations are shaded gray.
https://doi.org/10.1371/journal.pone.0174151.t001
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Fig 1. In vivo cetuximab sensitivity assay revealed diverse effect on 10 CTOS-derived xenogfrafts. A, Growth curves of subcutaneous
tumors originating from colorectal CTOS lines. Blue, treated with vehicle; orange, cetuximab (20 mg/kg); green, cetuximab (60 mg/kg). Mean
Cetuximab sensitivity assay using primary culture
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±SD is shown. N = 4–6 in each treated group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; 60 mg/kg cetuximab versus control; two-
way ANOVA with Bonferroni post-test. Regression, partially responsive, and resistant are explained in the text. The type of KRAS mutant is
indicated in superscript to the left of the line name. B, Microscopic images of vehicle-treated xenografts in A stained with EGFR antibody. Scale
bar, 50 μm. Grading by staining intensity is shown. C, Waterfall plot of cetuximab-treated tumor growth (differences from baseline). The average
sizes of cetuximab (60 mg/kg) treated tumors at day 21 were subtracted by the sizes at day 0 and the ratio compared to the average sizes at day
0 as follows: (VCmab (day 21)—VCmab (day 0))/ VCmab (day 0) x 100. Red bars, wildtype KRAS tumors; blue, KRAS mutants. D, Growth reduction
from control (vehicle treated) tumors. The average sizes of vehicle-treated tumors at day 11 were subtracted by the sizes of tumors treated with
cetuximab (60 mg/kg) and the ratio compared to the average sizes at day 11 as follows: (Vvehicle(day 11)- VCmab(day 11))/ Vvehicle(day 11) x 100.
https://doi.org/10.1371/journal.pone.0174151.g001
Fig 2. Establishment of ex vivo cetuximab sensitivity assays. A, Growth of C132 CTOSs cultured with the indicated doses of cetuximab for 7 days.
The relative growth at day 7 adjusted by day 0 is shown. Culture media are indicated. Mean±SD is shown. N = 3–6. Significance of the decrease in relative
growth. *P < 0.05, versus 0; one-way ANOVA with Bonferroni post-test. B, Western blots of lysates from C132 CTOSs cultured in the indicated media for
24 h. GF-, basal medium without any growth factor; SM, the standard CTOS medium; FBS, the FBS medium. Each antibody is indicated. C, Western blots
of lysates from C132 CTOSs treated with or without cetuximab (100 nM) for 2 h. CTOSs were cultured in the indicated media for 24 h before cetuximab
treatment. Cmab, cetuximab. D, Growth of C132 CTOSs cultured with the indicated doses of cetuximab for 7 days. CTOSs were cultured in the FBS
medium with (gray bars) or without (black bars, same as Fig 2A) 10 ng/ml HRG. The relative growth at day 7 adjusted by day 0 is shown. Mean±SD is
shown. N = 5–6. Significance of the decrease in relative growth. *P < 0.05, versus 0; one-way ANOVA with Bonferroni post-test. E, Results of the
reconstituted spheroid-based assay. The viable cell number in the spheroids was evaluated by ATP content, and the ratio to that of non-treated spheroids
is shown. CTOSs were cultured for 7 days in the indicated media with the indicated doses of cetuximab. Mean±SD is shown. N = 5–6. Significance of the
decrease in relative ATP content. ****P < 0.0001, versus 0; one-way ANOVA with Bonferroni post-test. F, Western blot evaluation of intracellular signaling
ex vivo. Reconstituted spheroids generated from C132 CTOSs were treated with or without 100 nM cetuximab for 2 h and then stimulated with or without 10
ng/ml of EGF for 15 min.
https://doi.org/10.1371/journal.pone.0174151.g002
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Suppression of ERK phosphorylation ex vivo paralleled KRAS mutant
cetuximab sensitivity in vivo
We performed ex vivo growth assays and signaling assays using reconstituted spheroids (Fig
3). Substantial differences were observed among the lines. The growth suppression by cetuxi-
mab in vivo was correlated to the ex vivo growth, as well as ERK phosphorylation with or with-
out EGF stimulation (S1 Fig).
The suppression of growth and ERK phosphorylation without EGF stimulation was distinct
between the regression and resistant groups (2/2 vs. 0/2), whereas the responses varied among
the partially responsive group. For example, C111 exhibited markedly discrepant results
between in vivo and ex vivo assays. In contrast, with EGF stimulation, ERK phosphorylation
was suppressed not only in the regression group, but also in the partially responsive group. It
was still not suppressed in the resistant group. The results indicate that the resistant group has
quite distinct characteristics that can be better distinguished by sustained ERK phosphoryla-
tion after cetuximab treatment in the presence of EGF stimulation ex vivo. In regards to the
mutational status of KRAS, the seven KRASmutant lines were distributed into two groups: par-
tially responsive (5/7) and resistant (2/7). Thus the KRASmutants were stratified into two
groups based on the effect of cetuximab not only in vivo but also ex vivo.
Combination of cetuximab and trametinib was effective in the partially
responsive group ex vivo
As the KRASmutant CRC CTOS lines in the partially responsive group exhibited a partial
response while those in the resistant group exhibited no response, we expected that combina-
tion therapy may improve the effect of cetuximab in the partially responsive group. First, we
screened 71 signaling inhibitors as single reagents using reconstituted spheroids derived from
C45 CTOSs, a line from the partially responsive group (Fig 4A and S1 Table). Four drugs
resulted in growth inhibition in which the relative ATP content was <0.5. One drug was tra-
metinib, a MEK inhibitor. As MEK is a downstream molecule of KRAS, we further studied
trametinib.
To determine the dose of trametinib for the combination treatment assays, we examined
mono-treatment with trametinib at various doses (Fig 4B and 4C). The C75 and C48 lines in
the resistant group were relatively resistant in the growth assay, although ERK phosphorylation
was remarkably inhibited in all lines examined when the doses were more than 10 nM (Fig 4B
and 4C). Therefore, we chose 10 nM for the growth assay (Fig 4D). Combination treatment in
the partially responsive group (C45, CB3) effected growth to a greater extent than trametinib
mono-treatment, but this was not observed in the resistant group (C75, C48) (Fig 4D). For the
signaling assay, we chose 5 nM trametinib with EGF treatment to ensure a clear combinatory
effect (Fig 4E). In the partially responsive group (C45, CB3), ERK phosphorylation was sup-
pressed more by combination treatment than trametinib alone, with (Fig 4E) or without (S2
Fig) EGF stimulation. In contrast, combination treatment did not suppress ERK phosphoryla-
tion in the resistant group (C75, C48).
Combination of cetuximab and trametinib was more effective in the
partially responsive group than in the resistant group in vivo
We examined the combined effect of cetuximab and trametinib in vivo (Fig 5) using xenograft
models generated by subcutaneously injecting the CTOSs. Mono-therapy with either cetuxi-
mab or trametinib had significant effects in the partially responsive group (C45, CB3), and the
combination of cetuximab and trametinib enhanced the effect; CB3 tumors stopped growing
Cetuximab sensitivity assay using primary culture
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Fig 3. Response of ERK phosphorylation to cetuximab treatment stratified KRAS mutants into two groups ex vivo. The result of the reconstituted
spheroid-based assay in each CTOS line is shown. The CTOS lines are ordered according to the results of the in vivo assay and the grouping indicated
Cetuximab sensitivity assay using primary culture
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after 14 days with combination therapy. In contrast, the lines in the resistant group (C75, C48)
exhibited a marginal effect with trametinib alone, and combination therapy seemingly had no
effect.
Discussion
We applied the CTOS method in this study of in vivo and ex vivo drug sensitivity assays. The
in vivo results were consistent with previous reports of the cetuximab resistance in KRAS
mutant CRCs. Here we revealed that KRASmutant CRC tumors have a wide range of sensitiv-
ity to cetuximab and can be divided into two groups: partially responsive and resistant. Lines
in the partially responsive group exhibit remarkable suppression of ERK phosphorylation after
cetuximab treatment in the presence of EGF stimulation. Combination therapy with cetuxi-
mab and trametinib, a MEK inhibitor, was more effective than mono-treatment in the partially
responsive group but not the resistant group.
Recently, the primary culture of cancer cells has progressed remarkably and is expected to
be applied to the prediction of sensitivity for individual patients. A phenotypic assay can be the
basis for studying mechanisms and developing biomarkers for a drug, especially when multiple
factors are involved [26]. CTOSs can be prepared efficiently from patient tumors, as well as
PDX or CTOS-derived xenografts. In addition, CTOSs can be proficiently cryopreserved as
spheroids. We previously reported that the ex vivo growth assay for selected CTOSs correlates
with the in vivo assay for various cancers and drugs[19, 22, 23, 27]. To the best of our knowl-
edge, this is the first report to perform and compare in vivo and ex vivo cetuximab sensitivity
assays side by side for a panel of CRC primary cultures. The results of the in vivo assays using
CTOS-derived xenografts were compatible with previous reports using PDX models. Further-
more, the ex vivo signaling assay reflected the in vivo sensitivity, although the ex vivo growth
did not completely reflect it.
The CTOS line C132 was sensitive to cetuximab in vivo but resistant ex vivo when the stan-
dard CTOS medium containing HER3 ligand was used. As the growth conditions in culture
can never be exactly the same as the microenvironment in vivo, the culture conditions need to
be adjusted to conform the results of the ex vivo growth assay to those of the in vivo assay or
patient responses. Various factors, such as the selection of growth factors and cell matrices and
co-culture with fibroblasts, should be optimized. On the other hand, signaling assays are more
promising because they assess the ‘potential capacity’ of cancer cells without long-term culture.
In this study, the suppression of ERK phosphorylation under high-dose EGF-stimulated con-
ditions was the best predictor of cetuximab sensitivity in vivo, although the functional role of
suppressing ERK phosphorylation is still not clear.
KRASmutant CRCs are thought to be generally resistant to cetuximab, as the overall sur-
vival, progression-free survival, and response rate have not improved in clinical trials [5, 6].
All KRASmutant xenograft tumors in this study grew after cetuximab treatment, which is con-
sistent with findings from previous clinical and pre-clinical studies [5, 14–17]. However, by
comparing the tumors to vehicle-treated controls, which is only allowed in experimental set-
tings, we demonstrated that KRASmutant CRCs can be divided into two groups. Tumor
growth was significantly suppressed by cetuximab treatment in the partially responsive group
but not the resistant group. In previous clinical reports, 10% of KRASmutant CRC exhibited
below. The type of KRAS mutant is indicated in superscript to the left of the line name. Upper panels: relative ATP content of reconstituted spheroids cultured
with the indicated doses of cetuximab for 7 days. Mean±SD is shown. N = 3–6. Significance of the decrease in relative ATP content. *P < 0.05, ***P < 0.001,
****P < 0.0001, versus 0; one-way ANOVA with Bonferroni post-test. Lower panels: ex vivo signaling assay by Western blot. Reconstituted spheroids were
treated with or without 100 nM cetuximab for 2 h and then stimulated with or without 10 ng/ml EGF for 15 min. Cmab, cetuximab.
https://doi.org/10.1371/journal.pone.0174151.g003
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Fig 4. Combination of cetuximab and trametinib was more effective in the partially responsive group ex vivo. A,
Screening of 71 drugs using reconstituted C45 spheroids. The spheroids were cultured with 100 nM of drug for 7 days. The
Cetuximab sensitivity assay using primary culture
PLOS ONE | https://doi.org/10.1371/journal.pone.0174151 March 16, 2017 11 / 17
drugs for which the relative ATP content was less than 0.5 are indicated. Mean values are shown. N = 4. B, Dose-response
curve of trametinib in four CTOS lines (the partially responsive group, C45 and CB3; the resistant group, C75 and C48).
The type of KRAS mutant is indicated in superscript to the left of the line name. C, Lysates of reconstituted spheroids from
four CTOS lines were subjected to Western blotting. The spheroids were treated with the indicated doses of trametinib for 4
h. The antibodies used are indicated. D, Relative ATP content of reconstituted spheroids cultured for 7 days with cetuximab
alone at the indicated doses (black bars), or in combination with 10 nM of trametinib (gray bars). Mean±SD is shown. N = 6.
Significance of the decrease in relative ATP content. *P < 0.05, **P < 0.01, ****P < 0.0001, versus 0; one-way ANOVA
with Bonferroni post-test. E, Western blots of lysates from the reconstituted spheroids treated with or without 100 nM
cetuximab, 5 nM trametinib, or a combination of 100 nM cetuximab and 5 nM trametinib for 2 h with or without stimulation
with 10 ng/ml EGF for 15 min.
https://doi.org/10.1371/journal.pone.0174151.g004
Fig 5. Combination of cetuximab and trametinib was more effective in the partially responsive group in
vivo. Growth curves of subcutaneous tumors generated by four CTOS lines (the partially responsive group, C45
and CB3; the resistant group, C75 and C48). Blue, treated with vehicle; orange, cetuximab (20 mg/kg) alone; green,
trametinib (0.3 mg/kg) alone; purple, combination of cetuximab (20 mg/kg) and trametinib (0.3 mg/kg). Mean±SD is
shown. N = 6 in each treated group. *P < 0.05, **P < 0.01, mono therapy with trametinib versus combination; two-
way ANOVA with Bonferroni post-test. The type of KRAS mutant is indicated in superscript to the left of the line
name.
https://doi.org/10.1371/journal.pone.0174151.g005
Cetuximab sensitivity assay using primary culture
PLOS ONE | https://doi.org/10.1371/journal.pone.0174151 March 16, 2017 12 / 17
disease control [28], and mutations in codon 13 (G13D) have been suggested to be more sensi-
tive to cetuximab than mutations in codon 12 [29, 30]. Thus, diverse sensitivities to cetuximab,
even in KRASmutants, have been suggested in clinical studies, although the characteristics
and mechanisms are poorly understood. When the previous reports using PDX are examined
carefully, they also indicate that KRASmutants exhibit various levels of partial response to
cetuximab [16, 17]. Thus, a partial response to cetuximab in KRASmutant CRC was observed
in both CTOS xenografts and PDX models, although the clinical relevance remains to be clari-
fied. In this study, attributing the different sensitivities to the type of KRASmutation is not
likely, as all four of the KRASmutations in codon 12 were in the relatively sensitive (partially
responsive) group, and two of the G13D (C97 and C75) lines were in different sensitivity
groups. Neither hotspot mutation in NRAS, BRAF, PIK3CA nor that of other genes which were
reportedly related to cetuximab resistance [15, 31–33] was able to distinguish the two groups.
Triad mutations of APC, KRAS, and genes in PI3K-AKT pathway were found only in the resis-
tant group. Since the number of the resistant lines are too small, further study should be per-
formed to ascertain whether the triad mutations can be a biomarker of the resistant group.
In this study, the CTOS method enabled ex vivo signaling assays of cancer cells in xenograft
tumors. Because KRAS is a downstream molecule in EGFR signaling, KRASmutant CRCs are
thought to be resistant to cetuximab due to constitutive activation of downstream signaling
[34–36]. In this study, increased ERK phosphorylation was suppressed by cetuximab in all of
the CTOS lines in the partially responsive group, indicating that ERK phosphorylation is still
dependent on upstream signaling in the majority of KRASmutant lines. The results are a sharp
contrast to most previous reports using established CRC cell lines, in which ERK phosphoryla-
tion is mostly resistant to cetuximab in KRASmutants [36–39]. The discrepancy may be attrib-
uted to the different culture conditions, or the partially responsive group may be rare in the
established cell lines. On the other hand, the two lines in the resistant group did not respond
to cetuximab treatment in regards to both growth and ERK phosphorylation. Particularly in
C48 CTOSs, ERK phosphorylation increased with cetuximab treatment. The activation of
compensatory pathways or relief of a negative feedback loop [40] may be involved.
Encouraged by the partial response to cetuximab in the partially responsive group, we inves-
tigated combination therapy with a MEK inhibitor. MEK is a downstream molecule of EGFR
and RAS signaling, and MEK inhibitor is expected to enhance the effect of cetuximab [36, 38].
In this study, ERK phosphorylation and the growth of CTOSs were suppressed in two KRAS
mutants in the partially responsive group after combination treatment. In contrast, the growth
of CTOSs in two KRASmutants in the resistant group were not affected by combination treat-
ment. As for ERK phosphorylation, cetuximab had no additional effect on MEK inhibition (Fig
4E). The activation of pathway molecules between EGFR and ERK may be independent of
EGFR activation. Alternatively, pathways other than MEK-ERK can be involved in cetuximab
resistance, as MEK inhibition had a minor effect on growth (Fig 4B and 4C).
Previous studies offer some examples in which the combination of cetuximab and a MEK
inhibitor is effective, even in resistant-type cell lines [36, 38]. The discrepancy may be due to
the difference between CTOSs and established cell lines, or a difference in the MEK inhibitors
used [37]. Resistant CTOS lines need to be accumulated to confirm the characteristics and
investigate the mechanism.
Taken together, our data support CTOSs of the same origin as a model shuttling system
between in vivo and ex vivo assays, especially for assessing the diversity of drug sensitivity. In
addition, this approach may be applicable to existing PDX models, although further studies
are required to clarify the similarity and difference between CTOS-derived xenograft and PDX
model. Furthermore, ex vivo assays using CTOS technology may be useful for screening drugs
and combination treatments or selecting patients for the therapies.
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Supporting information
S1 Fig. Scatter plots and regression lines showing the correlation between in vivo growth
reduction and various factors. Pearson’s correlation coefficients, R, and p-values are shown.
In vivo growth reduction was the average rate of growth reduction day 11 after the first treat-
ment with 60 mg/kg cetuximab in vivo. Ex vivo growth reduction was the average rate of
growth reduction day 7 after treatment with 100 nM cetuximab ex vivo. The reduced intensity
of ERK/AKT phosphorylation, which was adjusted by β-actin, was detected by Western blot-
ting with (EGF+) or without (EGF-) stimulation ex vivo.
(TIF)
S2 Fig. Ex vivo signaling assay of combination therapy with cetuximab and trametinib
without EGF stimulation. Western blotting of lysates from the reconstituted spheroids treated
with or without 100 nM cetuximab, 1 nM trametinib, or a combination of 100 nM cetuximab
and 1 nM trametinib for 2 h without EGF stimulation. The type of KRASmutant is indicated
in superscript to the left of the line name.
(TIF)
S1 Table. List and effect of the drugs used for screening. ATP content relative to that of non-
treated spheroids is shown. Effective results (<0.50) are indicated in pink.
(PDF)
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